Recent treatment of dry eye

Young Joo Shin

doi:10.5124/jkma.2019.62.4.218

Journal List > J Korean Med Assoc > v.62(4) > 1120196

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Shin: Recent treatment of dry eye

Pharmacotherapeutics

Journal of the Korean Medical Association 2019; 62(4): 218-223.

Published online: 11 April 2019

DOI: https://doi.org/10.5124/jkma.2019.62.4.218

Recent treatment of dry eye

Young Joo Shin, MD

Department of Ophthalmology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.

Corresponding author: Young Joo Shin. schinn@hanmail.net

Received 22 March 2019 Accepted 29 March 2019

Korean Medical Association

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Dry eye disease is a disease characterized by ocular irritation symptoms, tear film instability and ocular surface inflammation. Dry eye is due to aqueous tear deficiency or excessive tear evaporation, which causes damage to the ocular surface and is associated with ocular discomforts. A lot of therapy has been developed for treatment and management of dry eye disease. In this article, we review the current therapy for dry eye disease. We present the characteristics and efficacy of therapy for dry eye disease. We believe that our review will aid clinicians in the treatment of patients with dry eye disease.

Keywords: Dry eye disease, Tear film, Therapy

References

1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II definition and classification report. Ocul Surf. 2017; 15:276–283.

2. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, Sullivan DA. TFOS DEWS II pathophysiology report. Ocul Surf. 2017; 15:438–510.

3. Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benítez-del-Castillo J, Boboridis KG, Merayo-Lloves J, Rolando M, Labetoulle M. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016; 100:300–306.

4. Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology. 2017; 124:S20–S26.

5. Borchman D. The optimum temperature for the heat therapy for meibomian gland dysfunction. Ocul Surf. 2019; 02. 19. [Epub]. DOI: 10.1016/j.jtos.2019.02.005.

6. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, Seo KY, Tauber J, Wakamatsu TH, Xu J, Wolffsohn JS, Craig JP. TFOS DEWS II management and therapy report. Ocul Surf. 2017; 15:575–628.

7. Drug and Therapeutics Bulletin. The management of dry eye. BMJ. 2016; 353:i2333.

8. Pescosolido N, Parisi F, Buomprisco G, Librando A. New therapies in common ocular surface disorders. Clin Ter. 2013; 164:e405–e411.

9. Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017; 2:CD009327.

10. Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev. 2010; (9):CD006775.

11. Nam K, Kim HJ, Yoo A. Efficacy and safety of topical 3% diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials. Ophthalmic Res. 2019; 01. 17. [Epub]. DOI: 10.1159/000492896.

12. Holland EJ, Darvish M, Nichol KK, Jones L, Karpecki PM. Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: a systematic literature review. Ocul Surf. 2019; 03. 04. [Epub]. DOI: 10.1016/j.jtos.2019.02.012.

13. Keating GM. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye. Drugs. 2015; 75:911–922.

14. Zhao X, Xia S, Chen Y. Comparison of the efficacy between topical diquafosol and artificial tears in the treatment of dry eye following cataract surgery: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017; 96:e8174.

15. Burnstock G. The therapeutic potential of purinergic signalling. Biochem Pharmacol. 2018; 151:157–165.

16. Igarashi T, Fujita M, Yamada Y, Kobayashi M, Fujimoto C, Takahashi H, Igarashi T, Nakano Y, Suzuki H, Takahashi H. Improvements in signs and symptoms of dry eye after instillation of 2% rebamipide. J Nippon Med Sch. 2015; 82:229–236.

17. Lee H, Kim M, Park SY, Kim EK, Seo KY, Kim TI. Mechanical meibomian gland squeezing combined with eyelid scrubs and warm compresses for the treatment of meibomian gland dysfunction. Clin Exp Optom. 2017; 100:598–602.

18. Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol. 2013; 7:1797–1803.

19. Thode AR, Latkany RA. Current and emerging therapeutic strategies for the treatment of meibomian gland dysfunction (MGD). Drugs. 2015; 75:1177–1185.

20. Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea. 2013; 32:44–53.

21. Dogru M, Nakamura M, Shimazaki J, Tsubota K. Changing trends in the treatment of dry-eye disease. Expert Opin Investig Drugs. 2013; 22:1581–1601.

22. Keating GM. Lifitegrast ophthalmic solution 5%: a review in dry eye disease. Drugs. 2017; 77:201–208.

23. Albietz JM, Schmid KL. Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. Clin Exp Optom. 2018; 101:23–33.

24. Vora GK, Gupta PK. Intense pulsed light therapy for the treatment of evaporative dry eye disease. Curr Opin Ophthalmol. 2015; 26:314–318.

TOOLS

ORCID iDs: Young Joo Shin
https://orcid.org/0000-0003-4307-7000
Similar articles